Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Infectious diseases are prevalent in Cambodia, a country that is struggling with poor infrastructure. Streptococcus pneumoniae causes the most severe form of pneumonia and is now targeted by the pneumococcal conjugate vaccine. Dr Paul Turner is studying the effect of this vaccine in field conditions in SE Asia, as well as other direct applications such as the evaluation of a new diagnostic test for Typhoid and interventions to reduce the burden of infections acquired within hospitals.

Q: You are the Director of the Cambodia Oxford Medical Research Unit. Can you tell us a bit about what the unit does?

Paul Turner: The Cambodia Oxford Medical Research Unit or COMRU is one of the youngest members of the Oxford Tropical Network. We are based within a children's Hospital, the Angkor Hospital for Children in Siem Reap, Cambodia.

We run a programme of research which is directly relevant to the diseases that we see in children presented to the hospital and diseases that are particularly important in Cambodia: mostly infectious diseases. Pneumonia is the commonest cause of admission to the hospital. We also see a lot of typhus, typhoid and other infectious diseases that are common throughout the tropics.

Q: Can you tell us about your own personal research interests?

PT: My major research over the years has been childhood pneumonia, and in particular, one bacterium which is a common cause of the most severe presentations of pneumonia: Streptococcus pneumoniae. I am particularly interested in how that bacterium goes from asymptomatically colonising the back of a child's nose to then going on and causing disease, in particular pneumonia but also meningitis and sepsis.

Q: You are a microbiologist, what are some of the biggest challenges working as a microbiologist in a place like Cambodia?

PT: Cambodia is still struggling to recover from its recent history, in particular the Khmer Rouge genocide and the subsequent civil war. This has left the country with a very limited infrastructure and we have to overcome problems related to that on a daily basis.

Particular issues that we struggle with are erratic electricity: we have wonderful equipment but we often suffer early failures because of poor voltage stabilisation. We also struggle to maintain our supply chain: all of our reagents and consumables are imported and it can often be frustratingly slow to receive essential supplies.

Q: What are the most important lines of research that have emerged in the last 5-10 years?

PT: There has been a massive leap forward in terms of pneumococcal disease and pneumonia that occurred as a result of the introduction of the pneumococcal conjugate vaccine. This is a vaccine, or a series of vaccines, that stimulate the immune system in children and protect against up to 13 of the more than 90 types of this one bacterium that I am interested in. This has changed things enormously and we can now prevent a large proportion of these infections.

However, what we don't know so well is how this vaccine will work in less developed settings. The trials were mostly in high income countries and not in countries where there is a significant burden of antimicrobial resistance for example. We are working now to map the introduction of the vaccine in Cambodia and see if those impacts that we saw in the trials are seen in field conditions in South East Asia.

Q: Why does your line of research matter and why should we fund it?

PT: I think the important thing about our research is that it is very practical and based on diseases and infections that actually affect the population that we work with. We know that South East Asia is a very heterogenous region: there are relatively affluent areas but also often forgotten areas of poverty such as Cambodia, Myanmar and Laos. Our projects are rooted in those countries and really working towards improving the health of the population overall South East Asia, and where applicable we use that knowledge to improve the situation in other areas. We always try and make sure that the work we do is based on a clinical need.

Q: How does your research fit into translation medicine within the department?

PT: With our research projects, we always try to answer a practical question, one that is of immediate or almost immediate benefit to the population. An example is evaluating, with colleagues in Laos, a new diagnostic test for Typhoid that would lead to a quicker diagnosis in patients, and we hope a better outcome. Other examples are trying to understand the burden of infections that are acquired within the hospital, to come up with interventions that will work in settings such as ours. We are not really interested in abstract questions, we want to make a difference to our patient population.

Paul Turner

COMRU

The Cambodia Oxford Medical Research Unit (COMRU) is based in Siem Reap, northern Cambodia, which remains one of the poorest countries in South East Asia with extremely limited health services. Professor Paul Turner is working to better understand the key causes of infections in Cambodian children in order to improve diagnostic, treatment, and prevention strategies.

More podcasts related to Global Health

Mike English: Health services that deliver for newborns

Global Health

Basic hospital care may be key to saving newborn lives. Professor Mike English outlines a multidisciplinary project engaging policy-makers and practitioners in Kenya. This project demonstrated poor coverage of Nairobi’s 4.25 million population if a sick newborn baby needs quality hospital care. Using novel research approaches the team also identified how severe shortages of nurses contribute to poor quality of care for patients and negatively affect nurses themselves.

Tran Hien: Infectious diseases in the tropics

Global Health

Although incidence of malaria has decreased in Vietnam, the burden of infectious diseases remains high and weighs heavily on the health care system. Clinical research aims to allow investments to go further: findings in the laboratory, tested in clinical trials and then applied to the community, help improve diagnosis and management.

Ronald Geskus: Sophisticated biostatistics for complex clinical research

Global Health

The role of biostatisticians in clinical research is to contribute to trial design, by calculating sample size for example, and to help draw correct conclusions from the data, discriminating important information from noise. They are instrumental in the translation of a practical problem into a statistical model, and the translation of the result into practice.

Rogier Van Doorn: Research at OUCRU Hanoi

Global Health

Antibiotics are widely used in Vietnam, leading to widespread antimicrobial resistance. Monitoring antibiotic use helps inform the government to change treatment guidelines and implement antibiotic stewardship programmes. This may also prevent the transmission of resistant bacteria outside the country.

Heiman Wertheim: Clinical research in low and middle-income countries

Global Health

Drug resistant infections are a global crisis and we cannot focus on our own country only. Clinical trials in low and middle income countries where the burden is highest, as well as work with local communities and engagement with policy makers help influence public health policies.

Guy Thwaites: Tuberculosis meningitis

Global Health

Tuberculosis meningitis affects a fractions of TB patients but causes high levels of mortality and morbidity. A recent trial at OUCRU showed that aspirin can greatly improve outcomes. Such trial is typical of the work done in our Vietnam units, where all the research is focussed on improving the outcome for patients directly.

Motiur Rahman: OUCRU laboratory management

Global Health

OUCRU laboratories provide support to the unit’s extensive clinical research programme, from level 2 laboratory to SAPO 4 laboratory for high-risk pathogens responsible for zoonotic infections. Early diagnosis and detection of antimicrobial resistance helps prescribe the right medicine in time, contributing to better patient management.

Raph Hamers: Developing collaborative clinical trials in Indonesia

Global Health

Indonesia is a very populous country with a huge burden of infectious diseases such as TB, malaria, HIV and CNS infections. Running clinical trials requires high levels of expertise, currently developed and strengthened by institutions such as IOCRL (Universities of Indonesia and Oxford Clinical Research laboratory). Better collaborations will also help great ideas make a bigger impact.

Jeremy Day: Central nervous system and HIV infections in Vietnam

Global Health

Brain infections such as meningitis and encephalitis are highly debilitating diseases, and an accurate diagnostic is essential to give patients the best treatment available. For cryptococcal meningitis, clinical trials focus on prevention, for an early diagnosis, and novel ways to use existing treatments or repurpose old drugs.

Abhilasha Karkey: Connecting research with communities in Nepal

Global Health

Antimicrobial resistance is a huge burden in Nepal, particularly in hospitals where many nosocomial infections are caused by resistant pathogens. With limited resources, little infection controls and proper guidelines in place, finding out the main risk factors helps reduce infection rates within a hospital and better target vaccination campaigns.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.